Details for Patent: 11,666,538

Which drugs does patent 11,666,538 protect, and when does it expire?

Patent 11,666,538 protects CREXONT and is included in one NDA.

This patent has twenty-seven patent family members in twelve countries.

Summary for Patent: 11,666,538

Title:	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
Abstract:	The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
Inventor(s):	Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Assignee:	Impax Laboratories LLC
Application Number:	US17/959,681
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,666,538
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 11,666,538

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-001	Aug 7, 2024		RX	Yes	No			Y			TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-002	Aug 7, 2024		RX	Yes	No			Y			TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-003	Aug 7, 2024		RX	Yes	No			Y			TREATMENT OF PARKINSON'S DISEASE
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-004	Aug 7, 2024		RX	Yes	Yes			Y			TREATMENT OF PARKINSON'S DISEASE

International Family Members for US Patent 11,666,538

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014332024
Australia	2019284060
Australia	2021282393
Canada	2926082
China	105658211